LY 2090314

Drug Profile

LY 2090314

Alternative Names: GSK3 inhibitor - Eli Lilly; LY2090314

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class 3-ring heterocyclic compounds; Antineoplastics; Maleimides; Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • No development reported Acute myeloid leukaemia; Acute promyelocytic leukaemia

Most Recent Events

  • 25 Feb 2016 Eli Lilly terminates a phase I/II trial for Pancreatic cancer (metastatic disease) in USA (NCT01632306)
  • 08 Sep 2015 No recent reports on development identified - Phase-II for Acute myeloid leukaemia (Recurrent) and Acute promyelocytic leukaemia (Recurrent) in USA (IV)
  • 01 Mar 2013 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, First-line therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top